{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T08:26:25Z","timestamp":1786782385746,"version":"build-2736575974"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Cooperative Studies Program, Department of Veterans Affairs","award":["CSP #576"],"award-info":[{"award-number":["CSP #576"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Mixed manic\/hypomanic symptoms commonly occur in major depressive disorder (MDD), yet their prognostic and therapeutic significance following inadequate response to monoaminergic treatment remains uncertain. This secondary analysis of the Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial examined the prevalence, clinical correlates, and treatment implications of mixed features in 1522 nonbipolar outpatients with insufficient benefit from at least one prior monoaminergic agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To explore the prevalence, clinical correlates, and potential treatment implications of mixed features among patients with antidepressant-nonresponsive MDD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Participants were randomized to switching to bupropion sustained release (S-BUP), combining their current monoaminergic agent with bupropion sustained release (C-BUP), or augmenting treatment with aripiprazole (A-ARI). Mixed features were categorized into five exploratory, non-\n                      <jats:italic toggle=\"yes\">Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition<\/jats:italic>\n                      (DSM-5) levels based on the number and intensity of manic\/hypomanic symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 76.5% of participants endorsed at least one manic\/hypomanic symptom occurring \u201ca little\u201d or \u201ca lot,\u201d and 10.2% endorsed more than two symptoms occurring \u201ca lot.\u201d Higher mixed-feature levels were associated with greater depressive severity, functional impairment, and recurrent depressive episodes. Mixed features were not associated with treatment retention, response, or suicidal ideation. However, remission rates declined progressively across mixed-feature levels in the S-BUP group, a pattern not observed in the C-BUP or A-ARI groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Mixed features were highly prevalent and associated with greater clinical burden. Assessment of mixed features may provide clinically relevant information when selecting next-step pharmacologic strategies, particularly when considering a switch to bupropion sustained release.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261474121","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:27:26Z","timestamp":1786534046000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["What are the clinical implications of mixed features in major depressive disorder? A VAST-D report"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-9185","authenticated-orcid":false,"given":"Sidney","family":"Zisook","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Mental Health Service, Birmingham VA Health Care System, AL, USA"},{"name":"Department of Psychiatry, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[{"name":"VA Palo Alto Health Care System, CA, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Johnson","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Rush","sequence":"additional","affiliation":[{"name":"Duke University Medical School, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Planeta","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaia","family":"Mohamed","sequence":"additional","affiliation":[{"name":"VA New England Mental Illness Research, Education, and Clinical Center, VA Connecticut Healthcare System, West Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Angst J Cui L Swendsen J et al. (2010) Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. American Journal of Psychiatry 167(10): 1194\u20131201. https:\/\/doi.org\/10.1176\/appi.ajp.2010.09071011","DOI":"10.1176\/appi.ajp.2010.09071011"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Bailey RK Mokonogho J Kumar A (2019) Racial and ethnic differences in depression: Current perspectives. Neuropsychiatric Disease and Treatment 22: 603\u2013609. https:\/\/doi.org\/10.2147\/NDT.S128584","DOI":"10.2147\/NDT.S128584"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Beck AT Epstein N Brown G et al. (1993) Beck anxiety inventory. Journal of Consulting and Clinical Psychology 56: 893\u2013897. https:\/\/doi.org\/10.1037\/0022-006X.56.6.893","DOI":"10.1037\/0022-006X.56.6.893"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Benazzi F (2003) The role of gender in depressive mixed state. Psychopathology 36(4): 213\u2013217. https:\/\/doi.org\/10.1159\/000072792","DOI":"10.1159\/000072792"},{"key":"e_1_3_3_7_1","first-page":"1333","volume-title":"Psychiatry","author":"Demyttenaere K","year":"2024","unstructured":"Demyttenaere K, Heirman E (2024) Assessment tools in psychiatry. In: Tasman A, Riba MB, Alarc\u00f3n RD (eds) Psychiatry. Springer International Publishing, pp.1333\u20131364."},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Durgam S Kozauer SG Earley WR et al. (2025) Lumateperone for the treatment of major depressive disorder with mixed features or bipolar depression with mixed features: A randomized placebo-controlled trial. Journal of Clinical Psychopharmacology 45(2): 67\u201375. https:\/\/doi.org\/10.1097\/JCP.0000000000001964","DOI":"10.1097\/JCP.0000000000001964"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Endicott J Nee J Harrison W et al. (1993) Quality of life enjoyment and satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin 29(2): 321\u2013326. https:\/\/doi.org\/10.1037\/t49981-000","DOI":"10.1037\/t49981-000"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3): 199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Goldberg JF Siu C Mao Y et al. (2020) Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. Journal of Affective Disorders 277: 1045\u20131054. https:\/\/doi.org\/10.1016\/j.jad.2020.08.048","DOI":"10.1016\/j.jad.2020.08.048"},{"key":"e_1_3_3_12_1","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338","author":"Guy W","year":"1976","unstructured":"Guy W (1976) Clinical global impressions In: Guy W (ed.) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. National Institute of Mental Health, Psychopharmacology Research Branch, pp.217\u2013222."},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Hasin DS Sarvet AL Meyers JL et al. (2018) Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75(4): 336\u2013346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Kroenke K Spitzer RL Williams JB (2001) The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine 16(9): 606\u2013613. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Leverich GS Altshuler LL Frye MA et al. (2006) Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine sertraline and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry 163(2): 232\u2013239. https:\/\/doi.org\/10.1176\/appi.ajp.163.2.232","DOI":"10.1176\/appi.ajp.163.2.232"},{"issue":"2","key":"e_1_3_3_16_1","first-page":"343","article-title":"SAFTEE: A technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","unstructured":"Levine J, Schooler NR (1986) SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin 22(2): 343\u2013381.","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"McElroy SL Guerdjikova AI Romo-Nava F (2021) Diagnosing and treating major depressive episodes that lie along the mood disorders spectrum: Focus on depression with mixed features. CNS Spectrums 26(2): 133\u2013139. https:\/\/doi.org\/10.1017\/S1092852921000262","DOI":"10.1017\/S1092852921000262"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"McIntyre RS Soczynska JK Cha DS et al. (2015) The prevalence and illness characteristics of DSM-5-defined \u201cmixed feature specifier\u201d in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. Journal of Affective Disorders 172: 259\u2013264. https:\/\/doi.org\/10.1016\/j.jad.2014.09.026","DOI":"10.1016\/j.jad.2014.09.026"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Mohamed S Johnson GR Chen P et al. (2017) Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: The VAST-D randomized clinical trial. Journal American Medical Association 318(2): 132\u2013145. https:\/\/doi.org\/10.1001\/jama.2017.8036","DOI":"10.1001\/jama.2017.8036"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Mohamed S Johnson GR Vertrees JE et al. (2015) The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 229(3): 760\u2013770. https:\/\/doi.org\/10.1016\/j.psychres.2015.08.005","DOI":"10.1016\/j.psychres.2015.08.005"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Na KS Kang JM Cho SE (2021) Prevalence of DSM-5 mixed features: A meta-analysis and systematic review. Journal of Affective Disorders 282: 203\u2013210. https:\/\/doi.org\/10.1016\/j.jad.2020.12.149","DOI":"10.1016\/j.jad.2020.12.149"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Nusslock R Frank E (2011) Subthreshold bipolarity: Diagnostic issues and challenges. Bipolar Disorders 13(7\u20138): 587\u2013603. https:\/\/doi.org\/10.1111\/j.1399-5618.2011.00957.x","DOI":"10.1111\/j.1399-5618.2011.00957.x"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Pacchiarotti I Kotzalidis GD Murru A et al. (2020). Mixed features in depression: The unmet needs of diagnostic and statistical manual of mental disorders fifth edition. Psychiatric Clinics 43(1): 59\u201368. https:\/\/doi.org\/10.1016\/j.psc.2019.10.006","DOI":"10.1016\/j.psc.2019.10.006"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Patkar A Gilmer W Pae CU et al. (2012) A 6-week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 7(4): e34757. https:\/\/doi.org\/10.1371\/journal.pone.0034757","DOI":"10.1371\/journal.pone.0034757"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Perlis RH Cusin C Fava M (2014) Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. Psychological Medicine 44(7): 1361\u20131367. https:\/\/doi.org\/10.1017\/S0033291712000281","DOI":"10.1017\/S0033291712000281"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Perugi G Angst J Azorin JM et al. (2015) Mixed features in patients with a major depressive episode: The BRIDGE-II-MIX study. The Journal of Clinical Psychiatry 76(3): e351\u2013e358. https:\/\/doi.org\/10.4088\/JCP.14m09092","DOI":"10.4088\/JCP.14m09092"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Popovic D Vieta E Azorin JM et al. (2015) Suicide attempts in major depressive episode: Evidence from the BRIDGE-II-Mix study. Bipolar Disorders 17(7): 795\u2013803. https:\/\/doi.org\/10.1111\/bdi.12338","DOI":"10.1111\/bdi.12338"},{"key":"e_1_3_3_28_1","volume-title":"Columbia-Suicide Severity Rating Scale (C-SSRS)","author":"Posner K","year":"2008","unstructured":"Posner K, Brent D, Lucas C, et al. (2008) Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia University Medical Center."},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Rush AJ Trivedi MH Ibrahim HM et al. (2003) The 16-Item Quick Inventory of Depressive Symptomatology (QIDS) clinician rating (QIDS-C) and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54(5): 573\u2013583. https:\/\/doi.org\/10.1016\/S0006-3223(02)01866-8","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_3_3_30_1","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan DV","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al. (1998) The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59(Suppl 20): 22\u201333.","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Shim IH Bahk WM Woo YS et al. (2018) Pharmacological treatment of major depressive episodes with mixed features: A systematic review. Clinical Psychopharmacology and Neuroscience 16(4): 376. https:\/\/doi.org\/10.9758\/cpn.2018.16.4.376","DOI":"10.9758\/cpn.2018.16.4.376"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Stahl SM Morrissette DA Faedda G et al. (2017) Guidelines for the recognition and management of mixed depression. CNS Spectrums 22(2): 203\u2013219. https:\/\/doi.org\/10.1017\/S1092852917000165","DOI":"10.1017\/S1092852917000165"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Suppes T Ostacher M (2017) Mixed features in major depressive disorder: Diagnoses and treatments. CNS Spectrums 22(2): 155\u2013160. https:\/\/doi.org\/10.1017\/S1092852917000256","DOI":"10.1017\/S1092852917000256"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Suppes T Silva R Cucchiaro J et al. (2016) Lurasidone for the treatment of major depressive disorder with mixed features: A randomized double-blind placebo-controlled study. American Journal of Psychiatry 173(4): 400\u2013407. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15060770","DOI":"10.1176\/appi.ajp.2015.15060770"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Targum SD Suppes T Pendergrass JC et al. (2016) Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 68: 9\u201314. https:\/\/doi.org\/10.1016\/j.pnpbp.2016.02.007","DOI":"10.1016\/j.pnpbp.2016.02.007"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Trivedi MH (2009) Tools and strategies for ongoing assessment of depression: A measurement-based approach to remission. Journal of Clinical Psychiatry 70(Suppl 6): 26\u201331. https:\/\/doi.org\/10.4088\/JCP.8133su1c.04","DOI":"10.4088\/JCP.8133su1c.04"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Trivedi MH Rush AJ Wisniewski SR et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: Implications for clinical practice. American Journal of Psychiatry 163(1): 28\u201340. https:\/\/doi.org\/10.1176\/appi.ajp.163.1.28","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Tundo A Musetti L Betr\u00f2 S et al. (2023) Are anxious and mixed depression two sides of the same coin? Similarities and differences in patients with bipolar I II and unipolar disorders. European Psychiatry 66(1): e75. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2445","DOI":"10.1192\/j.eurpsy.2023.2445"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Verdolini N Hidalgo-Mazzei D Murru A et al. (2018) Mixed states in bipolar and major depressive disorders: Systematic review and quality appraisal of guidelines. Acta Psychiatrica Scandinavica 138(3): 196\u2013222. https:\/\/doi.org\/10.1111\/acps.12896","DOI":"10.1111\/acps.12896"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Vieta E Martinez-Aran A Goikolea JM et al. (2002) A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry 63(6): 508\u2013512. https:\/\/doi.org\/10.4088\/JCP.v63n0607","DOI":"10.4088\/JCP.v63n0607"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.03.007"},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Wisniewski SR Rush AJ Balasubramani GK et al. (2006) Self-rated global measure of the frequency intensity and burden of side effects. Journal of Psychiatric Practice 12(2): 71\u201379. https:\/\/doi.org\/10.1097\/00131746-200603000-00002","DOI":"10.1097\/00131746-200603000-00002"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Young RC Biggs JT Ziegler VE et al. (1978) A rating scale for mania: Reliability validity and sensitivity. The British Journal of Psychiatry 133(5): 429\u2013435. https:\/\/doi.org\/10.1192\/bjp.133.5.429","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","unstructured":"Zisook S Johnson GR Tal I et al. (2019) General predictors and moderators of depression remission: A VAST-D report. American Journal of Psychiatry 176(5): 348\u2013357. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18091079","DOI":"10.1176\/appi.ajp.2018.18091079"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Zisook S Tal I Weingart K et al. (2016) Characteristics of US veteran patients with major depressive disorder who require \u201cnext-step\u201d treatments: A VAST-D report. Journal of Affective Disorders 206: 232\u2013240. https:\/\/doi.org\/10.1016\/j.jad.2016.07.023","DOI":"10.1016\/j.jad.2016.07.023"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261474121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261474121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261474121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:47:46Z","timestamp":1786780066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261474121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":44,"alternative-id":["10.1177\/02698811261474121"],"URL":"https:\/\/doi.org\/10.1177\/02698811261474121","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"02698811261474121"}}